StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3036% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Research by Year

Research — Laboratory supplies (standalone through FY2018, $M) ($M)

Vertex Pharmaceuticals Research: $50.6M in FY2018, up 10.5% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2018
50.6
Period ended Dec 31, 2018
Change on a year earlier
+10.5%
45.8 in FY2017
History
6 years
Since FY2013
Sources
4
Documents cited below

Where the FY2018 figure comes from

“|| Laboratory supplies and other direct expenses | 50,578 | 45,822 | 43,151 | 4,756 | 10 | % | 2,671 | 6 | %”

Source: Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗

Reported in Form 10-Q / 10-K MD&A (Research Expenses Disaggregation Table).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedResearch — Laboratory supplies (standalone through FY2018, $M) ($M)Year on yearSource
FY2018Dec 31, 201850.6+10.5%Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
FY2017Dec 31, 201745.8+6.0%Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
FY2016Dec 31, 201643.2+16.4%Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
FY2015Dec 31, 201537.1-2.6%Form 10-K (a201710k-main.htm, filed 2018-02-15) ↗
FY2014Dec 31, 201438.1+5.8%Form 10-K (a201610k-main.htm, filed 2017-02-23) ↗
FY2013Dec 31, 201336–Form 10-K (a201510k-main.htm, filed 2016-02-16) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Research ($M), annual FY2013–FY2018 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-res-lab-supplies

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.